AGXT
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
WB 1:500-1:2000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.6 mg/mL
Buffer
PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20°C. Avoid freeze / thaw cycles.
Target
AGXT
(Alanine Glyoxylate Aminotransferase (AGXT))
Andere Bezeichnung
AGXT
Hintergrund
AGT,AGT1,Agxt,AGXT1,Alanine glyoxylate aminotransferase,Alanine glyoxylate aminotransferase3,Alanine--glyoxylate aminotransferase,EC 2.6.1.44,EC 2.6.1.51,Hepatic peroxisomal alanine glyoxylate aminotransferase,Hepatic peroxisomal alanine:glyoxylate aminotransferase,L alanine glyoxylate aminotransferase 1,MS773,PH1,Serine pyruvate aminotransferase,Serine--pyruvate aminotransferase,Serine--pyruvate aminotransferase,mitochondrial,Serine:pyruvate aminotransferase,SPAT,SPT,SPYA,TLH6,Serine-pyruvate aminotransferase is an enzyme that in humans is encoded by the AGXT gene. This gene is expressed only in the liver and the encoded protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification. Mutations in this gene, some of which alter subcellular targetting, have been associated with type I primary hyperoxaluria. Defects in AGXT are the cause of hyperoxaluria primary type 1 (HP1), also known as primary hyperoxaluria type I (PH1) and oxalosis I. HP1 is a rare autosomal recessive inborn error of glyoxylate metabolism characterized by increased excretion of oxalate and glycolate, and the progressive accumulation of insoluble calcium oxalate in the kidney and urinary tract.